1st Circ. Affirms $26M Award In Sulindac Injury Suit

Law360, Los Angeles (May 2, 2012, 8:19 PM EDT) -- The First Circuit on Wednesday affirmed a $26 million award given to a woman who suffered a near-fatal reaction after taking Mutual Pharmaceutical Co. Inc.'s generic drug Sulindac, ruling that design defect claims aren't preempted by federal law.

The decision raises a question over the scope of the Federal Food, Drug and Cosmetic Act that only the Supreme Court can decide, the First Circuit said. The courts are split over whether the Supreme Court's ruling in Pliva Inc. v. Mensing — which held that state law...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.